Allogene Therapeutics (ALLO) SVP sells shares in tax-related sell-to-cover
Allogene Therapeutics' SVP and Chief Technical Officer, Benjamin Machinas Beneski, sold 2,867 shares of common stock at $2.50 each. This transaction was not a discretionary trade but a mandatory "sell to cover" to satisfy tax withholding obligations related to the vesting of restricted stock units. Following the sale, Beneski still directly holds 195,338 shares of Allogene Therapeutics, indicating a minimal impact on his overall holdings.
Allogene Therapeutics Stock Gains Momentum from Sector Tailwinds ()
Allogene Therapeutics is experiencing a surge in stock value due to a positive shift in the biotechnology sector, driven by strategic acquisitions and licensing deals. The cell therapy specialist's clinical pipeline is attracting institutional investors, pushing its stock close to its yearly peak with an approximately 96% gain since the start of the year. Future growth hinges on concrete data readouts from its research pipeline and further industry consolidation.
ALLO Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Allogene Therapeutics Inc (ALLO) as of March 30, 2026. It indicates a "Neutral" overall technical consensus, with a detailed breakdown of moving averages, momentum indicators like RSI and MACD, and key support and resistance levels. The analysis suggests ALLO is currently trading above its 60-day and 200-day moving averages, indicating a potentially bullish long-term trend.
5 Penny Stocks with Potential to Rise 1000 Percent
Allogene Therapeutics (NASDAQ: ALLO) is highlighted as a penny stock with significant growth potential due to its innovative pipeline. The company is progressing with its lead program, cema-cel, in a pivotal Phase 2 trial for large B-cell lymphoma and advancing ALLO-329 for autoimmune diseases. Key data readouts are expected in April and June 2026, which could be catalysts for the stock.
Allogene Therapeutics advances CAR T therapy to expand access for patients
Allogene Therapeutics is making strides in CAR T therapy, aiming to revolutionize patient care through innovative cell therapy developments. The company is focused on improving access to advanced treatments and holds promise for patients with severe autoimmune diseases. This includes the introduction of ALLO-329, a next-generation CAR-T therapy utilizing its Dagger technology platform.
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Allogene Therapeutics (NASDAQ:ALLO) has received a "Moderate Buy" consensus recommendation from eleven brokerages, with an average one-year price target of $8.56. The stock recently saw a significant jump of 17.6% and beat quarterly EPS estimates. Insiders have sold a notable amount of shares recently, while institutional investors hold a substantial portion of the company's stock.
Allogene Therapeutics, Inc.(NasdaqGS:ALLO) added to S&P Biotechnology Select Industry Index
Allogene Therapeutics, Inc. (NasdaqGS:ALLO) has been added to the S&P Biotechnology Select Industry Index. This news follows several recent financial announcements from the company, including Q4 2025 earnings results and presentations at various industry summits. Allogene Therapeutics is a clinical-stage immuno-oncology company focused on developing allogeneic T cell product candidates for cancer and autoimmune diseases.
If You Invested $1,000 in Allogene Therapeutics (ALLO)
This article analyzes the historical performance of investing $1,000 in Allogene Therapeutics (ALLO) over various periods, showing significant losses over five and ten years, while noting a gain in the past year. It also provides an overview of Allogene Therapeutics, detailing its focus on allogeneic CAR T cell therapies for cancer and autoimmune diseases, its core platform, key clinical programs, and relevant regulatory and intellectual property aspects. The company's stock has underperformed the S&P 500 over the last decade.
Piper Sandler Analysts Bullish on Allogene Therapeutics (ALLO) Ahead of Key ALPHA3 Data Readout
Piper Sandler analysts are bullish on Allogene Therapeutics (NASDAQ:ALLO), maintaining an "Overweight" rating and increasing the price target to $8 ahead of the anticipated ALPHA3 study data readout in April 2026. The clinical-stage biotechnology company's ALPHA3 trial, assessing cema-cel for large B-cell lymphoma, is a key focus for investors, with Piper Sandler expecting a significant MRD clearance advantage. Allogene Therapeutics also reported a Q4 2025 net loss of $38.81 million but has extended its cash runway into Q1 2028.
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2025 earnings call transcript
This is an earnings call transcript for Allogene Therapeutics, Inc. (NASDAQ:ALLO) for the fourth quarter of 2025. The full transcript provides details of the company's financial performance and operational updates during that period.
David Chang Sells 47,763 Shares of Allogene Therapeutics (NASDAQ:ALLO) Stock
Allogene Therapeutics CEO David Chang sold 47,763 shares of the company's stock on March 16th, reducing his stake by 0.92%. The transaction, valued at over $117,000, leaves him with approximately 5.15 million shares. Despite the insider selling, analysts maintain a "Moderate Buy" rating for ALLO with an average price target of $8.50, and the company recently beat EPS estimates.
Allogene Therapeutics (NASDAQ:ALLO) SVP Sells $11,942.45 in Stock
Allogene Therapeutics (NASDAQ:ALLO) SVP Benjamin Machinas Beneski sold 4,835 shares of the company's stock on March 16th for a total of $11,942.45, reducing his stake by 2.38%. The company's Q1 earnings beat estimates, and analysts generally rate the stock as a "Moderate Buy" with an average price target of $8.50. The stock is currently trading around $2.15.
Allogene (NASDAQ: ALLO) SVP share sale funds tax withholding
Allogene Therapeutics' SVP and Chief Technical Officer, Benjamin Beneski, sold 4,835 shares of Common Stock at a weighted average price of $2.47 per share. This sale was not discretionary but was a mandated "sell to cover" transaction to fulfill tax withholding obligations tied to the vesting of restricted stock units. Following this transaction, Beneski retains 198,205 direct shares in the company.
Allogene (ALLO) CEO executes 47,763-share tax sell-to-cover transaction
Allogene Therapeutics President and CEO David D. Chang sold 47,763 shares of common stock at $2.47 per share. This transaction was a mandatory "sell to cover" to meet tax withholding obligations from vested restricted stock units, not a discretionary trade. After the sale, Chang directly holds 5,150,599 common shares, with additional indirect holdings through various family trusts.
Allogene Therapeutics (NasdaqGS:ALLO) Stock Forecast & Analyst Predictions
Allogene Therapeutics (ALLO) is projected to grow earnings and revenue significantly, by 40% and 60.6% per annum respectively, although it is expected to remain unprofitable for the next three years with a forecast return on equity of -48.5%. The company, which develops off-the-shelf CAR T therapies, has seen recent analyst updates including upgraded EPS estimates and decreased price targets, alongside various clinical trial updates and insider activity.
Allogene Therapeutics targets new approach to autoimmune conditions with ALLO-329
Allogene Therapeutics has unveiled ALLO-329, an experimental allogeneic CAR-T therapy for autoimmune diseases, powered by Dagger technology. This therapy aims to reduce or eliminate the need for lymphodepletion, making cell therapy safer and more accessible for patients. ALLO-329 represents a significant advancement in CAR-T therapies for severe autoimmune conditions, though further research and clinical validation are needed.
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2025 earnings call transcript
This document is a Q4 2025 earnings call transcript for Allogene Therapeutics, Inc. (NASDAQ:ALLO). It provides a detailed record of the company's financial performance and operational updates as discussed by management during the call. The transcript serves as an important resource for investors and analysts to understand the company's recent results and future outlook.
Allogene Therapeutics (NASDAQ: ALLO) RSUs Vest, 47,763 Common Shares
Allogene Therapeutics (NASDAQ: ALLO) reported the vesting of 47,763 Restricted Stock Units (RSUs) on March 13, 2026, as detailed in a Form 144 SEC filing. These shares of Common Stock were granted under the issuer's equity compensation plan. The filing indicates an intent for potential resale under Rule 144, though actual sales or execution details are not included.
Citizens reiterates Allogene stock rating on pipeline progress
Citizens has reaffirmed its Market Outperform rating and a $5.00 price target for Allogene Therapeutics (NASDAQ:ALLO), citing pipeline progress and discounted valuation. The company's ALPHA3 pivotal study is on track for futility analysis in April 2026, and proof-of-concept data for ALLO-329 in autoimmune disease is expected in June. Despite current stock levels being deemed slightly overvalued by InvestingPro, Allogene reported a cash position of $258.3 million, holds more cash than debt, and has shown strong momentum with a 103% return over the last six months.
Citizens reiterates Allogene stock rating on pipeline progress
Citizens has reaffirmed its Market Outperform rating and $5.00 price target for Allogene Therapeutics (NASDAQ:ALLO), citing continued pipeline progress and a discounted EPS and revenue multiple analysis. The company reported a cash position of $258.3 million and strong stock momentum with a 103% return over the last six months. However, InvestingPro analysis suggests the stock is currently slightly overvalued.
Short Interest in Allogene Therapeutics, Inc. (NASDAQ:ALLO) Expands By 19.8%
Short interest in Allogene Therapeutics, Inc. (NASDAQ:ALLO) increased by 19.8% to 23,927,216 shares in February. This represents approximately 12.3% of the company's shares sold short, with a days-to-cover ratio of 4.0 days. Recent analyst ratings indicate a "Moderate Buy" consensus, with several firms raising price targets, while some insider selling has also occurred.
Cancer and autoimmune push: inside Allogene’s 2026 CAR T trials
Allogene Therapeutics reported Q4 and full-year 2025 financial results, with a cash runway extending into Q1 2028. The company is nearing critical milestones for its CAR T programs, including an interim futility analysis of the ALPHA3 trial in April 2026 for large B-cell lymphoma and initial data from the RESOLUTION trial for autoimmune disease in June 2026. Despite a net loss of $190.9 million in 2025, Allogene maintains a positive outlook due to disciplined expense management and strategic advancement of its clinical pipeline.
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4
Allogene Therapeutics reported a narrower-than-expected loss of 17 cents per share in Q4 2025, surpassing the Zacks Consensus Estimate of a 25-cent loss. The company, which has no marketed products, did not report any sales but saw its shares surge 80% year-to-date. Allogene provided 2026 guidance, expecting full-year operating expenses of approximately $210 million and cash burn of about $150 million, while also providing updates on its key pipeline programs, including the ALPHA3 study and the RESOLUTION basket study for autoimmune diseases.
Allogene Therapeutics (NASDAQ: ALLO) outlines allogeneic CAR T plans and risks
Allogene Therapeutics (NASDAQ: ALLO) has filed its annual report (10-K) detailing its allogeneic CAR T-cell therapy pipeline for cancer and autoimmune diseases. The company is advancing three core programs: cema-cel for large B-cell lymphoma (LBCL) in a pivotal Phase 2 trial (ALPHA3), ALLO-316 for renal cell carcinoma (RCC) with RMAT designation, and ALLO-329 for systemic autoimmune diseases. Allogene anticipates interim ALPHA3 MRD data in April 2026 and initial ALLO-329 proof-of-concept data in June 2026, while highlighting substantial financial losses, dependence on lead assets, and manufacturing/regulatory complexities.
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
Allogene Therapeutics reported its Q4 and full year 2025 financial results, highlighting progress in its cema-cel ALPHA3 trial for B-cell lymphoma and the ALLO-329 trial for autoimmune diseases. The company expects interim data from the ALPHA3 trial in April 2026 and proof-of-concept data for ALLO-329 in June 2026, while extending its cash runway into Q1 2028 with $258.3 million in cash, cash equivalents, and investments.
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4
Allogene Therapeutics (ALLO) reported a narrower-than-expected loss of 17 cents per share in Q4 2025, beating the Zacks Consensus Estimate of 25 cents. The company, which lacks a marketed product, saw its shares surge 80% year-to-date. Allogene provided a 2026 guidance anticipating full-year operating expenses of around $210 million and a cash burn of approximately $150 million, while progressing with its cema-cel, ALLO-329, and ALLO-316 pipeline candidates.
Allogene (NASDAQ: ALLO) details 2025 loss, pipeline data milestones and cash runway
Allogene Therapeutics reported its fourth quarter and full-year 2025 financial results, highlighting a net loss of $190.9 million or $0.87 per share for the year. The company provided updates on key pipeline milestones, including an interim futility analysis for the ALPHA3 trial of cema-cel in April 2026 and proof-of-concept data for the RESOLUTION trial of ALLO-329 in autoimmune disease in June 2026. Allogene ended 2025 with $258.3 million in cash, cash equivalents, and investments, extending its cash runway into the first quarter of 2028.
El Pollo Loco Posts Upbeat Q4 Results, Joins Kyivstar Group, American Public Education And Other Big Stocks Moving Higher On Friday
El Pollo Loco Holdings Inc (NASDAQ:LOCO) saw a significant stock jump after reporting better-than-expected fourth-quarter financial results, with earnings of $0.25 per share and sales of $123.515 million, surpassing analyst estimates. Benchmark also upgraded the stock from Hold to Buy. The article highlights other companies like VEON Ltd, Kyivstar Group Ltd, and American Public Education, Inc. that also experienced stock gains due to strong performances or positive news.
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
Allogene Therapeutics announced its Q4 and full-year 2025 financial results, reporting a cash runway extended into Q1 2028 with $258.3 million in cash, cash equivalents, and investments. The company is advancing its pivotal Phase 2 ALPHA3 trial for cema-cel in LBCL, with interim futility analysis expected in April 2026, and its Phase 1 RESOLUTION trial for ALLO-329 in autoimmune diseases, with initial data planned for June 2026. Allogene aims to revolutionize CAR T therapy delivery for both oncology and autoimmune conditions through its proprietary technologies.
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2025 Earnings Call Transcript
Allogene Therapeutics reported its Q4 2025 earnings, exceeding expectations with an EPS of $-0.17 against an anticipated $-0.22551. The company highlighted its strategic focus on advancing two key programs, SemiCell for large B-cell lymphoma and ALLO-329 for autoimmune diseases, while extending its cash runway into 2028. Upcoming milestones include interim futility results for SemiCell in April and proof-of-concept data for ALLO-329 in June.
Allogene Therapeutics 2025 10-K: Net loss $190.9M, EPS $(0.87); runway into Q1 2028
Allogene Therapeutics reported a net loss of $190.9 million or $(0.87) per share for fiscal year 2025, an improvement from the previous year, with loss from operations at $(209.3) million. The company has $258.3 million in cash, cash equivalents, and investments, projecting a financial runway into Q1 2028 due to cost and workforce reductions.
Allogene Therapeutics: Q4 Earnings Snapshot
Allogene Therapeutics Inc. (ALLO) reported a Q4 loss of $38.8 million, or 17 cents per share, surpassing Wall Street's expectation of a 25-cent loss. For the full year, the company's loss narrowed to $190.9 million, or 87 cents per share. The company's shares ended Thursday trading at $2.47, up from $2.06 a year ago.
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
Allogene Therapeutics released its Q4 and full-year 2025 financial results, highlighting a strong cash position of $258.3 million extending its runway into Q1 2028. The company is advancing its lead programs, including the pivotal Phase 2 ALPHA3 trial for cema-cel in large B-cell lymphoma and the Phase 1 RESOLUTION trial for ALLO-329 in autoimmune diseases, with key interim data expected in April and June 2026, respectively. Allogene aims to demonstrate the scalability of allogeneic CAR T therapy and its potential to revolutionize treatment in both oncology and autoimmune disorders.
Allogene Therapeutics: Q4 Earnings Snapshot
Allogene Therapeutics Inc. (ALLO) reported a fourth-quarter loss of $38.8 million, or 17 cents per share, surpassing Wall Street's expectations of a 25-cent loss. The company's annual loss narrowed to $190.9 million, or 87 cents per share. Shares of Allogene Therapeutics were trading at $2.47 at the close of trading on Thursday.
Allogene Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview
Allogene Therapeutics Inc (ALLE) is projected to report a loss of 22 cents per share. This earnings preview, sourced from Refinitiv, suggests investors should anticipate a negative financial outcome for the company. The report is brief, indicating it's a preliminary estimate ahead of the official earnings release.
Allogene Therapeutics (ALLO) Expected to Announce Earnings on Thursday
Allogene Therapeutics (ALLO) is scheduled to announce its Q4 2025 earnings after market close on Thursday, March 12, 2026. Analysts project an EPS of ($0.25) and revenue of $0.0020 million. Insider selling has been observed recently, with executives disposing of shares, though insiders still own 13.20% of the company, and institutional investors hold 83.63%.
Insider Selling: Allogene Therapeutics (NASDAQ:ALLO) SVP Sells 7,132 Shares of Stock
Allogene Therapeutics (NASDAQ:ALLO) SVP Benjamin Machinas Beneski sold 7,132 shares of the company's stock on March 2nd at an average price of $2.60, totaling over $18,500. This sale decreased his position by 3.39%. The stock is currently trading around $2.53, with analysts maintaining a "Moderate Buy" consensus and an average price target of $8.40.
Allogene Therapeutics Teases April ALPHA3 Futility Data, Details Autoimmune CAR-T Program at TD Cowen
Allogene Therapeutics (NASDAQ: ALLO) presented key updates at TD Cowen's 46th Annual Healthcare Conference, including upcoming futility data in April for its ALPHA3 trial of cema-cel, a CD19 CAR-T therapy for frontline large B-cell lymphoma. The company also detailed its autoimmune CAR-T program, ALLO-329, which uses a dual CD19/CD70 "Dagger" design to potentially reduce or eliminate lymphodepletion, with initial proof-of-concept data expected in June 2026. Allogene emphasized its "Allogene XL" therapies' scalable manufacturing, aiming for 20,000–60,000 doses annually at an estimated cost of $10,000–$20,000 per dose, and eyes a potential $5 billion market opportunity.
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update
Allogene Therapeutics, Inc. (Nasdaq: ALLO) will report its fourth quarter and full year 2025 financial results and provide a business update on March 12, 2026, after market close. The announcement will be followed by a live audio webcast and conference call. The company specializes in developing "off-the-shelf" allogeneic CAR T cell products for cancer and autoimmune diseases.
Allogene Therapeutics (NASDAQ: ALLO) files Form 144 for 7,132 RSU shares
Allogene Therapeutics, Inc. (NASDAQ: ALLO) has filed a Form 144 notice for 7,132 shares of Common Stock. This filing is related to the vesting of a restricted stock unit award on February 28, 2026. Morgan Stanley Smith Barney LLC is listed as the broker, and NASDAQ as the market for the intended sale.
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update
Allogene Therapeutics will report its fourth quarter and full year 2025 financial results and provide a business update on March 12, 2026, after market close. This will be followed by a live audio webcast and conference call. The clinical-stage biotechnology company is focused on developing allogeneic CAR T products for cancer and autoimmune disease.
ALLO Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Allogene Therapeutics (ALLO), analyzing its income statement, balance sheet, and cash flow for fiscal year 2024 and prior years. It highlights the company's profitability, growth, leverage, liquidity, and cash flow, revealing a low financial health score of 40/100 due to significant revenue decline and negative operating margins, despite strong liquidity and low debt. The analysis also covers key financial metrics, ratios, and frequently asked questions, indicating concerns about earnings quality and ability to cover interest payments.
Primecap Management Co. CA Has $8.78 Million Stock Position in Allogene Therapeutics, Inc. $ALLO
Primecap Management Co. CA significantly increased its stake in Allogene Therapeutics (NASDAQ:ALLO) by 23.8% in Q3, now holding over 7 million shares valued at approximately $8.78 million. Other institutional investors like Vanguard and Goldman Sachs also boosted their holdings, leading to institutional ownership of about 83.63% of the company's stock. Analysts generally rate ALLO as a "Moderate Buy" with a target price of $8.40, while the stock currently trades around $2.78.
Allogene (ALLO) Clinical Hold on CAR-T Studies Removed by FDA
The FDA has removed the clinical hold on all five of Allogene Therapeutics' (ALLO) allogeneic CAR T ("AlloCAR T") studies, which had been in place since October 2021. The hold was lifted after investigations concluded that a reported chromosomal abnormality with unclear clinical significance was not related to Allogene's manufacturing process or gene-editing technology and had no clinical significance. This decision allows Allogene to resume clinical development for its AlloCAR T pipeline candidates.
Allogene Therapeutics Faces Financial Challenges Despite Industry Moves
Allogene Therapeutics Inc. (NASDAQ: ALLO) shares fell over 7% following an earnings report that highlighted a negative revenue trajectory and significant operational hurdles. Despite strategic shifts and clinical trial progress, the company faces internal inefficiencies and intense competition within the biopharmaceutical sector.
Allogene Therapeutics unveils plans for Virtual Oncology Summit
Allogene Therapeutics announced its participation in Citi’s 2026 Virtual Oncology Leadership Summit on February 18. The company will provide updates on its investigational allogeneic CAR T pipeline and its overall corporate strategy. A webcast will be available on Allogene's Investor Relations site for stakeholders.
Dr. Chang (NASDAQ: ALLO) discloses 5.2% Allogene ownership stake
Dr. David D. Chang has reported a beneficial ownership stake of 5.2% in Allogene Therapeutics, Inc. (NASDAQ: ALLO), amounting to 12,101,223 shares. This figure includes shares issuable from stock options and holdings through various family trusts. The disclosure was made in a SCHEDULE 13G filing, indicating a passive investment, and is based on 224,730,144 shares outstanding as of November 4, 2025.
Follicular Lymphoma Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsights | AstraZeneca, InnoCare Pharma, Allogene Therapeutics, HUTCHMED, Sound Biologics, Xynomic
The "Follicular Lymphoma Pipeline Insight, 2025" report by DelveInsight evaluates over 45 companies developing more than 50 treatment therapies for Follicular Lymphoma, covering clinical and commercial aspects from preclinical to marketed phases. Key companies like InnoCare Pharma, AstraZeneca, and Allogene Therapeutics are advancing therapies such as ICP 248, ALLO-501, and acalabrutinib. Recent significant developments include FDA approvals for epcoritamab-bysp in combination therapies and tafasitamab-cxix, as well as EC approval for lisocabtagene maraleucel, signaling a dynamic landscape with ongoing clinical advancements.
Allogene Therapeutics (NASDAQ:ALLO) Cut to "Sell" at Wall Street Zen
Wall Street Zen downgraded Allogene Therapeutics (NASDAQ:ALLO) from "hold" to "sell." Despite this, the consensus analyst rating for ALLO remains a "Moderate Buy" with an average price target of $8.40. Insider selling has been observed, with executives selling shares, while the stock currently trades around $1.80.
Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year?
Allogene Therapeutics (ALLO) has significantly outperformed the Medical sector this year, returning 23.4% compared to the sector's 0.9% average. The company holds a Zacks Rank of #2 (Buy), reflecting positive analyst sentiment and an improving earnings outlook. McKesson (MCK), another Medical stock, has also outpaced the sector with a 14% year-to-date return and a Zacks Rank #2 (Buy).
